Improving Detection of AL Amyloidosis (IDEA)
Multiple grants to be awarded $250,000; $150,000; & $50,000
一个wardees
Boston University School of Medicine, an internationally recognized center for amyloidosis research and treatment with one of the largest biorepositories of amyloidosis patient samples in the world, is developing precision diagnostics seeking to provide early detection and optimal management of AL amyloidosis.
CellPrint Biotechnology, LLCis partnering with leading researchers to develop a proprietary technology aiming to discover the unknown relationships between molecular expression in immune cells and the clinical status of patients, hoping to provide new insights about pathophysiology and help identify novel biomarkers and drug targets.
City of Hopeis an NCCN-designated cancer center with multiple myeloma and amyloidosis treatment and research programs pursuing the exploration of left atrial (LA) strain as a novel marker for early cardiac amyloidosis.
Mayo Clinicis on a strategic mission to use the latest advances in science and technology to help improve health outcomes for patients, including harnessing artificial intelligence for early detection of AL amyloidosis.
Memorial Sloan Kettering Cancer Centeris collaborating with Clinical Directors Network (CDN) to conduct an online CME-accredited program aiming to increase awareness of AL amyloidosis and to inform the prevalence, incidence, and diagnostic pathways for AL amyloidosis patients receiving care in NYC.
National and Kapodistrian University of Athens, School of Medicineis a team of physicians, pharmacologists, biologists, medicinal chemists, and radiopharmacists who are developing a 99m Tc-radiolabeled tracer aiming to offer high affinity for amyloid fibrils, efficient biodistribution in tissues predominantly affected by systemic amyloidosis, and binding in immunoglobulin light chain amyloid deposits.
Protego Biopharmais developing small molecule pharmacological chaperones and UPR modulators for the treatment of protein misfolding diseases.
Tufts Medical Center,through its active plasma cell disease program and translational research laboratory, is leveraging its extensive expertise in plasma cell biology, genomics, and modern techniques of genetic analysis to help improve the lives of AL amyloidosis patients.
University Medical Center Utrechtcombines a team of clinicians and scientists in a focused translational research program aiming to improve the diagnosis and treatment of patients with AL amyloidosis.
Overview
Each year in the United States, an estimated 4,500 new patients are diagnosed with AL amyloidosis[1], a life-threatening blood cell disorder that occurs when blood plasma cells in the bone marrow produce amyloid deposits, which build up in vital organs and eventually cause organ deterioration[2]。The disease can affect different organs in different people, but the most frequently affected organs are the heart, kidneys, liver, spleen, gastrointestinal tract and nervous system.Further complicating treatment for the disease, almost one-third of patients with AL amyloidosis will visit five or more physicians before being diagnosed, and nearly three-quarters are diagnosed over a year after initial symptoms occur[3]。This can lead to a poor prognosis due to the delay in diagnosis of AL amyloidosis, which frequently presents with non-specific symptoms that can mimic other, more common conditions[4]。多达30%的patients with AL amyloidosis die within the first year after diagnosis.[5]
To that end, Johnson & Johnson Innovation together with Janssen Global Services invites innovators to submit ideas aimed at optimizing AL amyloidosis disease detection and early diagnosis in theImprovingDEtection of AL一个myloidosis (IDEA) QuickFire Challenge. Multiple awardees with the best products, technologies, or methodologies will receive grant funding in increments up to $250,000, $150,000, and $50,000, access to the Johnson & Johnson Innovation – JLABS ecosystem, and mentorship* from experts at the Johnson & Johnson Family of Companies.
*As appropriate by expertise and/or regulatory considerations
[1]https://amyboidosis.org/facts/al/#
[2]Lousada I, Comenzo RL, Landau H, et al. Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium. Advances in Therapy. 2015;32(10):920-928.
[3]McCausland KL, et al. Patient. 2018;11(2):207-216.
[4]梅奥诊所。淀粉样变性诊断和治疗。https://mayocl.in/3jk50g4。2021年1月访问。
[5]Merlini G, et al. Light chain amyloidosis: the heart of the problem. Haematologica. 2013;98(10):1492-1495.
Why this Challenge Matters
In AL amyloidosis, plasma cells in the bone marrow produce abnormal light chains that form amyloid deposits, which build up in vital organs and eventually cause organ deterioration[1]。一个L amyloidosis can affect different organs in different people, but the most frequently affected organs are the heart, kidneys, liver, spleen, GI tract and nervous system.
Still a rare condition, diagnosis of AL amyloidosis can be delayed and symptoms may be non-specific, resulting in misdiagnosis.
Knowledge and expertise in how to measure and assess symptoms commonly seen in this population can be critical for timely diagnosis, as well as improving access to diagnostic tools and innovating the application of AI and EMR-based interventions to improve detection.
一个t Johnson & Johnson Innovation, we believe a good idea can come from anywhere, and it’s our goal to find new and innovative technologies that aim to provide potential solutions to patients from around the world. Working together, we can spark the next great idea that could change the trajectory of health.
[1]Baker KR, Rice L. The Amyloidoses: clinical features, diagnosis and treatment. Methodist Debakey Cardiovasc J. 2012;8(3):3-7. doi:10.14797/mdcj-8-3-3
一个reas of Interest
We’re interested in products, technologies, or methodologies, which may be translational or clinical in nature.
We encourage applications from visionaries – including entrepreneurs/startups, hematologists, cardiologists, radiologists, and nephrologists familiar with AL amyloidosis, basic science researchers, and patient advocates - working on potentially ground-breaking ideas or technologies in AL amyloidosis that aim to:
- Increase awareness of disease symptoms and improve recognition of disease among HCPs
- Improve identification/testing of patients
- 开发血液测试/生物标志物淀粉样变
- Develop nuclear medicine imaging with amyloid-specific tracers
- Create AI-based screening tools
- Facilitate EMR-based research
- Produce Epidemiology studies
一个wards
- Multiple grants in increments up to $250,000, $150,000, and $50,000
- 一个ccess to the Johnson & Johnson Innovation – JLABS ecosystem
- Mentorship from experts of the Johnson & Johnson Family of Companies
Criteria
Potential solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:
- Technology/Research Concept and Focus on AL Amyloidosis
- Team Quality & Capabilities
- Degree of Innovation & Uniqueness
- Market/Research Validation
- Level of Feasibility
- Resources & Milestone
- Plans for use of Funds
- Scalability (ability to translate to other areas outside of their practice)
- Considerations of accessibility across socioeconomic groups
- 部署能力
FAQs
What if I’m having trouble accessing the portal/website?
Make sure your browser is up to date and accepting cookies.
Can I submit supporting documents (for example a video) as part of my application?
You will have the opportunity and are encouraged to upload supporting materials such as slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is two minutes.
Is it ok if some of the information I submit is confidential?
Do not submit confidential information. Only non-confidential information should be submitted and anything you submit will be treated as non-confidential.
What happens with IP (Intellectual Property)?
一个s this is a no-strings-attached arrangement, JLABS does not acquire any IP. Any IP creation and/or protection remains the sole responsibility of the inventors.
Is a patent required to apply?
No, a patent is not required to apply. However, you should not submit any information that you wish to keep confidential or that may negatively impact upon the future patentability of your invention.
What kind of science / technology is appropriate for the Challenges?
We encourage applications from entrepreneurs, innovators, hematologists, cardiologists, radiologists, nephrologists, basic science researchers and patient advocates working with technologies such as Artificial Intelligence (AI), EMR-based research, and beyond to develop potentially ground-breaking ideas aimed at optimizing AL amyloidosis disease detection and early diagnosis.
Who is eligible to apply?
Each Challenge has its own terms & conditions that can be found prior to filling out the application.
Do applicants have to reside in the United States in order to apply?
No, this is a global challenge.
Who can I contact if I have questions about the Challenges or the application process?
Please contact[email protected]with any questions.
Where do I apply? And do I have to complete the application in one sitting?
Go to https://jnjquickfire.secure-platform.com to learn more. From there you will be directed to set up an account. You are able to save your work and log back in to finish at a later time if needed.
Timeline
一个bout the Janssen Pharmaceutical Companies of Johnson & Johnson
在Janssen，我们正在创造一个疾病过去的未来。我们是Johnson＆Johnson的制药公司，不懈地努力，通过与科学作斗争，以独创性的方式与疾病作斗争，并充满内心的绝望，使各地的患者成为现实。我们专注于可以使最大差异的医学领域：心血管和新陈代谢，免疫学，传染病和疫苗，神经科学，肿瘤学和肺动脉高压。
一个bout Johnson & Johnson Innovation
Johnson & Johnson Innovation, LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers; Johnson & Johnson Innovation – JLABS; Johnson & Johnson Innovation – JJDC, Inc.; and our business development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. JLABS provides the laboratories, expertise, education, tools and resources needed to help life science startups thrive, all with no strings attached. A Johnson & Johnson Innovation Center for Device Innovation at the Texas Medical Center (CDI @ TMC) has been established to accelerate the development of medical devices. For more information about Johnson & Johnson Innovation, please visit:www.jnjinnovation.com.
一个bout Johnson & Johnson Innovation - JLABS
Johnson & Johnson Innovation-JLABS (JLABS)是一个开放innovati的全球网络on ecosystems, enabling and empowering innovators across a broad healthcare spectrum including pharmaceutical, medical device, consumer and health tech sectors to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS, we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS also produces campaigns to seek out the best science called QuickFire Challenges. For more information, visitwww.www.2574design.comor follow@JLABS。